IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2SCIENCE IMMUNOLOGYIF16.32022-09-3010OA
Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)CANCER RESEARCHIF16.62016-07-153PRE
Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82016-04-0141OAAI
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle GrowthMOLECULAR THERAPY-NUCLEIC ACIDSIF02016-01-0175OAAI
P2-Quinazolinones and Bis-Macrocycles as New Templates for Next-Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK-2748 and MK-6325CHEMMEDCHEMIF3.42015-03-1021PREAI
Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and RabbitMOLECULAR THERAPY-NUCLEIC ACIDSIF02015-01-0128OAAI
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants (vol 56, pg 4161, 2012)ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52014-08-012OAAI
siRNA-Mediated Knockdown of P450 Oxidoreductase in Rats: A Tool to Reduce Metabolism by CYPs and Increase Exposure of High Clearance CompoundsPHARMACEUTICAL RESEARCHIF4.32014-07-0116PREAI
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant VariantsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52012-08-01210OA
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42012-03-02160OA
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureACS MEDICINAL CHEMISTRY LETTERSIF42011-01-1237OAAI
MK-5172: A NOVEL HCV NS3/4A PROTEASE INHIBITOR WITH POTENT ACTIVITY AGAINST KNOWN RESISTANCE MUTANTSJOURNAL OF HEPATOLOGYIF332010-04-012PREAI
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorJOURNAL OF MEDICINAL CHEMISTRYIF6.82010-02-17157PREAI
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52010-01-01127OAAI
Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2-P4 MacrocyclesJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-07-2221PREAI
Bismacrocyclic Inhibitors of Hepatitis C NS3/4a ProteaseANGEWANDTE CHEMIE-INTERNATIONAL EDITIONIF16.92008-11-0552PREAI
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis CNS3/4A proteaseJOURNAL OF THE AMERICAN CHEMICAL SOCIETYIF15.62008-03-14147PREAI
Identification of a small molecule nonpeptide active site β-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteasesJOURNAL OF MEDICINAL CHEMISTRYIF6.82004-10-30131PREAI